NCT04552470View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo

3 matching placebo tablets taken twice a day (BID)

DRUG

PF-06882961

Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.

Trial Locations (1)

192-0071

P-one clinic, Keikokai medical corporation, Hachiōji

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04552470 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter